Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: A dynamic individual-based approach

Vaccine

Volumn 30, Issue 32, 2012, Pages 4866-4871

  Vanni, Tazio ^a   Mendes Luz, Paula ^b   Foss, Anna ^a   Mesa Frias, Marco ^a   Legood, Rosa ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Cervical cancer; Cost effectiveness; Economic modelling; Human papillomavirus; Screening; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DISEASE MODEL; DRUG COST; FEMALE; GOVERNMENT; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNITY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; VIRUS TRANSMISSION;

ADULT; BRAZIL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MALE; MIDDLE AGED; MODELS, ECONOMIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84862524258     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.087     Document Type: Article

References (58)

1. Ferlay J., Shin H-R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
2. INCA Estimativa 2012-Incidencia de Cancer no Brasil 2011, Available from: http://www.inca.gov.br/estimativa/2012/ [cited 6.12.11].
3. Muñoz N., Bosch F.X., de Sanjosé S., Herrero R., Castellsagué X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527.
4. von Krogh G., Lacey C.J.N., Gross G., Barrasso R., Schneider A. European guideline for the management of anogenital warts. Int J STD AIDS 2001, 12(Suppl. 2):40-47.
5. Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
6. The Future II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(May (19)):1915-1927.
7. Kim J.J., Andres-Beck B., Goldie S.J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007, 97(November (9)):1322-1328.
8. Goldie S.J., Kim J.J., Kobus K., Goldhaber-Fiebert J.D., Salomon J., O'Shea M.K.H., et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007, 25(33):6257-6270.
9. Edmunds W.J., Medley G.F., Nokes D.J. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999, 18(23):3263-3282.
10. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L.R., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006, 24(27-28):5571-5583.
11. Viscidi R.P., Schiffman M., Hildesheim A., Herrero R., Castle P.E., Bratti M.C., et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection. Cancer Epidemiol Biomark Prev 2004, 13(February (2)):324-327.
12. Trottier H., Mahmud S., Prado J.C.M., Sobrinho J.S., Costa M.C., Rohan T.E., et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008, 197(10):1436-1447.
13. Insinga R., Dasbach E., Elbasha E. Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 2009, 9(1):119.
14. Insinga R.P., Dasbach E.J., Elbasha E.H. Structural differences among cost-effectiveness models of human papillomavirus vaccines. Expert Rev Vaccines 2008, 7(7):895-913.
15. Kim J.J., Kuntz K.M., Stout N.K., Mahmud S., Villa L.L., Franco E.L., et al. Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007, 166(July (2)):137-150.
16. Canfell K., Barnabas R., Patnick J., Beral V. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 2004, 91(3):530-536.
17. Taira A.V., Neukermans C.P., Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004, 10(November (11)):1915-1923.
18. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13(1):28-41.
19. Dasbach E.J., Insinga R.P., Elbasha E.H. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG: Int J Obstet Gynaecol 2008, 115(8):947-956.
20. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337(July):a769.
21. Insinga R.P., Dasbach E.J., Elbasha E.H., Puig A., Reynales-Shigematsu L.M. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007, 26(1):128-139.
22. Van de Velde N., Brisson M., Boily M-C. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010, 28(33):5473-5484.
23. Sanders G.D., Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003, 9(January (1)):37-48.
24. Fontaine J., Hankins C., Mayrand M.-H., Lefevre J., Money D., Gagnon S., et al. High levels of HPV-16 DNA are associated with high-grade cervical lesions in women at risk or infected with HIV. AIDS 2005, 19(8):785-794.
25. Garnett G.P. An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect 2002, 78(February (1)):7-12.
26. Garnett G.P. The influence of behavioural heterogeneity on the population level effect of potential prophylactic human immunodeficiency virus type 1 vaccines. J R Stat Soc: Ser A (Stat Soc) 1998, 161(2):209-225.
27. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006, 3:e138.
28. Van de Velde N., Brisson M., Boily M-C. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007, 165(April (7)):762-775.
29. Vanni T., Legood R., Franco E.L., Villa L.L., Luz P.M., Schwartsmann G. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. Int J Cancer 2011, 129(3):671-679.
30. Vanni T., Karnon J., Madan J., White R.G., Edmunds W.J., Foss A.M., et al. Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics 2011, 29(1):35-49. 10.2165/11584600-000000000-00000.
31. INCA Nomenclatura brasileira para laudos cervicais e condutas preconizadas: recomendações para profissionais de saúde 2006, Instituto Nacional do Cancer, Ministério da Saude, Rio de Janeiro, Brazil.
32. Pecorelli S, Ngan HY, Hacker NF. Staging classification and clinical practice guidelines for gynaecological cancers; third editions. Available from: [cited 29.08.2011]. http://www.figo.org/publications/staging_classifications.
33. Methodological guidelines for appraisals on health technology assessment for the Ministry of Health of Brazil 2008, Available from: http://portal.saude.gov.br/portal/saude/visualizar_texto.cfm?idtxt=26776 [cited 25.07.08].
34. Vanni T., Luz P.M., Grinsztejn B., Veloso V.G., Foss A., Mesa-Frias M., et al. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country. Int J Cancer 2011, 131(2):E96-E104.
35. Central Intelligence Agency The World Factbook 2009, Available from: https://www.cia.gov/library/publications/the-world-factbook/index.html [cited 10.12.09].
36. National Health Surveillance Agency (ANVISA) 2006, Available from: http://www.anvisa.gov.br/divulga/imprensa/clipping/2006/agosto/290806.pdf [cited 20.10.11].
37. WHO Macroeconomics and health: investing in health for economic development: report of the commission on macroeconomics and health 2001, World Health Organization, Geneva.
38. Goldie S.J., Gaffikin L., Goldhaber-Fiebert J.D., Gordillo-Tobar A., Levin C., Mahe C., et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005, 353(November (20)):2158-2168.
39. Goldie S.J., Diaz M., Kim S-Y., Levin C.E., Van Minh H., Kim J.J. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008, 26(Suppl. 12):M17-M29.
40. Popper K. Conjectures and refutations: the growth of scientific knowledge 2003, Routledge, Oxford.
41. Colantonio L., Gómez J.A., Demarteau N., Standaert B., Pichón-Rivière A., Augustovski F. Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 2009, 27(40):5519-5529.
42. Steben M. Update on Gardasil (quadrivalent human papillomavirus [HPV] 6/11/16/18 vaccine) clinical trial efficacy results. EUROGIN 2010 2010.
43. Jit M., Chapman R., Hughes O., Choi Y.H. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343:d5775.
44. UK Department of Health Your guide to the HPV vaccination from September 2012 2012, Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_133345 [cited 06.04.12].
45. Reynales-Shigematsu L.M., Rodrigues E.R., Lazcano-Ponce E. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Arch Med Res 2009, 40(6):503-513.
46. Jha P., Bangoura O., Ranson K. The cost-effectiveness of forty health interventions in Guinea. Health Policy Plan 1998, 13(January (3)):249-262.
47. Portaria GM/MS No 3.124 2006, Ministério da Saúde. Saúde INdC-Md (Ed.).
48. Coupé V.M.H., Bogaards J.A., Meijer C.J.L.M., Berkhof J. Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening. Vaccine 2012, 30(10):1813-1822.
49. Insinga R.P., Perez G., Wheeler C.M., Koutsky L.A., Garland S.M., Leodolter S., et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomark Prev 2010, 19(June (6)):1585-1594.
50. Sycuro L.K., Xi L.F., Hughes J.P., Feng Q., Winer R.L., Lee S-K., et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008, 198(October (7)):971-978.
51. Insinga R., Dasbach E., Elbasha E., Liaw K-L., Barr E. Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agents Dis 2007, 2(1):15.
52. Insinga R.P., Wheeler P.G., Koutsky C.M., Garland L.A., Leodolter S.M., Joura S., et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomark Prev 2011, 20(2):287-296.
53. Murillo R., Almonte M., Pereira A., Ferrer E., Gamboa O.A., Jerónimo J., et al. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 2008, 26(Suppl. 11):L37-L48.
54. Nanda K., McCrory D.C., Myers E.R., Bastian L.A., Hasselblad V., Hickey J.D., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000, 132(10):810-819.
55. Goldhaber-Fiebert J.D., Stout N.K., Salomon J.A., Kuntz K.M., Goldie S.J. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008, 100(5):308-320.
56. Mitchell M.F., Schottenfeld D., Tortolero-Luna G., Cantor S.B., Richards-Kortum R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998, 91(4):626-631.
57. Pretorius R.G., Zhang W.-H., Belinson J.L., Huang M.-N., Wu L.-Y., Zhang X., et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004, 191(2):430-434.
58. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13:28-41.